About MIRA Pharmaceuticals, Inc. - Common Stock (MIRA)
MIRA Pharmaceuticals, Inc. is a biotechnology company focused on the research, development, and commercialization of innovative therapeutic solutions for various medical conditions. The company emphasizes advancing drug development by leveraging cutting-edge technology and scientific expertise to create novel treatments. With a commitment to improving patient outcomes, MIRA Pharmaceuticals aims to address unmet medical needs through its pipeline of pharmaceutical products that target specific diseases and disorders. The company collaborates with research institutions, healthcare professionals, and other stakeholders to ensure the efficacy and safety of its offerings in the healthcare landscape. Read More
From AI-driven cancer breakthroughs and non-opioid pain innovation to 5G mmWave expansion, mining advancements , and AI-powered mobility , emerging growth stocks are igniting fresh investor momentum this week. Making headlines with major catalysts and clinical or commercial milestones that align with today’s biggest market trends in AI, biotech, clean tech, and digital transformation .
MIRA Pharmaceuticals shares are trading significantly higher on Thursday following the announcement of new preclinical data for its lead candidate Mira-55.
Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA's position in a $70 billion non-opioid pain market.
Mira Pharmaceuticals shares surged 68.94% in after-hours trading after the company reported promising preclinical results for its pain treatment candidate, Mira-55.
Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA's advancing programs including Ketamir-2 and MIRA-55
Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The drug showed rapid and predictable absorption, a favorable duration of action supporting once-daily dosing, and no CNS side effects typically seen with ketamine.
SKNY transaction strengthens MIRA pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30% weight loss and nicotine craving reversal in preclinical studies.
Manuscript accepted for publication in Frontiers in Pharmacology, "Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagonism" details Ketamir-2's superior performance in two validated neuropathic pain models and supports advancement to Phase 2a clinical trials by year-end 2025.
